Sara Tolaney from Dana-farber , what's new in breast cancer CDK 4/6 inhibitor in adjuvant setting, 34% reduction in recurrence SERDs elacestrant for ESR1 mutated mHR+ breast cancer, adjuvant trial ongoing AKT inhibitor (Capivsertib)+ fulvestrant coming soon Oral anti-Her2 agent: tucatinib ADC Saci, T-Dxd IO: Pembrolizumab for stage IV breast ca (PD-L1 CPS>=10%), neoadjuvant for TNBC regardless PD-L1 status, pCR rate in 60% |